Relative efficacies of amyloid β peptide (Aβ) binding proteins in Aβ aggregation

Journal of Neuroscience Research

Volumn 46, Issue 1, 1996, Pages 58-66

  Webster, Scott ^a   Rogers, Joseph ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

1 antichymotrypsin; Alzheimer's disease; apolipoprotein E; C1q; serum amyloid P

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; AMYLOID P COMPONENT; APOLIPOPROTEIN E; BINDING PROTEIN; COMPLEMENT COMPONENT C1Q; PREALBUMIN;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; NERVE CELL DEGENERATION; NEUROTOXICITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ASSEMBLY; SENILE PLAQUE;

ALPHA 1-ANTICHYMOTRYPSIN; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; COMPLEMENT C1Q; HUMANS; PREALBUMIN; PROTEIN BINDING; SERUM AMYLOID P-COMPONENT; SPECTROMETRY, FLUORESCENCE; THIAZOLES;

EID: 0029758030     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19961001)46:1<58::AID-JNR8>3.0.CO;2-E     Document Type: Article

References (79)

1. 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52: 487-501.
2. 1-antichymotrypsin. Neurobiol Aging 11:123-129.
3. Adams RD, Victor MV (1985): "Principles of Neurobiology." 3rd Ed. New York: McGraw-Hill.
4. Axelrad MA, Kisilevlky R, Willmer J, Chen SJ, Skinner M (1982): Further characterization of amyloid-enhancing factor. Lab Invest 47:139-146.
5. Brachova L, Lue L-F, Schultz J, El Rashidy T, Rogers J (1993): Association cortex, cerebellum, and serum concentrations of C1q and factor B in Alzheimer's disease. Mol Brain Res 18: 329-334.
6. Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C, Glabe C (1992): Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J Biol Chem 267:546-554.
7. Burgevin MC, Passat M, Daniel N, Doble A (1994): Congo Red protects against toxicity of β-amyloid peptides on rat hippocampal neurones. NeuroReport 5:2429-2432.
8. Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, Frangione B (1995): Fibrillogenesis in Alzheimer's disease of amyloid ßpeptides and apolipoprotein E. Biochem J 306:599-604.
9. Coria F, Castano E, Prelli F, Larrondo-Lillo M, Van Duinen S, Shelanski ML, Frangione B (1988): Isolation and characterization of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab Invest 58:454-458.
10. Diedrich JF, Minnigan H, Carp RI, Whitaker JN, Race R, Frey W II, Haase AT (1991): Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes. J Virol 65: 4759-4768.
11. Duong T, Pommier EC, Scheibel AB (1989): Immunodetection of the amyloid P component in Alzheimer's disease. Acta Neuropathol 78:429-437.
12. Einstein ER (1982): "Proteins of the Brain and CSF in Health and Disease." Springfield, IL: Charles C Thomas.
13. 1-antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation. Proc Natl Acad Sci USA 92:2313-2317.
14. Evans KC, Berger EP, Cho C-G, Weisgraber KH, Lansbury PT (1995): Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci USA 92:763-767.
15. 1-Antichymotrypsin binding to Alzheimer Aβ peptides is sequence specific and induces fibril disaggregation in vitro. J Neurochem 61:298-305.
16. Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T, Frangione B (1993): The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 293:27-30.
17. Glenner GG (1980): Amyloid deposits and amyloidosis: The beta-fibrilloses. N Engl J Med 302:1283-1292.
18. Glenner GG, Wong CW (1984): Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120:885-890.
19. Goldgaber D, Schwarzman AI, Bhasin R, Gregori L, Schmechel D, Saunders AM, Roses AD, Strittmatter WJ (1993): Sequestration of amyloid β-peptide. Ann NY Acad Sci 695:139-143.
20. Hamazaki H (1995): Amyloid P component promotes aggregation of Alzheimer's beta-amyloid peptide. Biochem Biophys Res Commun 211:349-353.
21. Hawkins PN, Rossor MN, Gallimore JR, Miller B, Moore EG, Pepys MB (1994): Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. Biochem Biophys Res Commun 201: 722-726.
22. Janciauskiene S, Garcia de Frutos P, Carlemalm E, Dahlback B, Eriksson S (1995): Inhibition of Alzheimer β-peptide fibril formation by serum amyloid P component. J Biol Chem 270: 26041-26044.
23. Jarret JT, Berger EP, Lansbury PT (1993): The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693-4697.
24. Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ (1994): β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J Immunol 152:5050-5059.
25. Kalaria RN, Galloway PG, Perry G (1991): Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders. Neuropathol Appl Neurobiol 17:189-201.
26. Kisilevsky R (1992): Proteoglycans, glycosaminoglycans, amyloid-enhancing factor, and amyloid deposition. J Intern Med 232: 515-516.
27. Lehtimaki T, Pirttila T, Mehta PD, Wisniewski HM, Frey H, Nikkari T (1995): Apolipoprotein E (apoE) polymorphism and its influence on apoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum Genet 95:39-42.
28. LeVine H (1993): Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci 2:404-410.
29. LeVine H (1995): Thioflavine T interaction with amyloid β-sheet structures Amyloid. Int J Exp Clin Invest 2:1-6.
30. Li XA, Hatanaka K, Guo L, Kitamura Y, Yamamoto A (1994): Binding of serum amyloid P component to heparin in human serum. Biochim Biophys Acta 1201:143-148.
31. 1-chymotrypsin. Alzh Dis Assoc Dis 8:241-249.
32. Lorenzo A, Yankner BA (1994): β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red. Proc Natl Acad Sci USA 91:12243-12247.
33. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372:92-94.
34. Mantyh PW, Ghilardi JR, Rogers S, DeMaster E, Allen CJ, Stimson ER, Maggio JE (1993): Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of β-amyloid peptide. J Neurochem 61:1171-1174.
35. Mashige F, Shimizu T, Iijima S, Ohkubo A (1992): Analysis for cerebrospinal fluid proteins by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Clin Chem 38:2008-2012.
36. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985): Amyloid plaque core protein in Alzheimer's disease and Down's syndrome. Proc Natl Acad Sci USA 82:4245-4249.
37. Matsubara E, Frangione B, Ghiso J (1995): Characterization of apolipoprotein J-Alzheimer's Aβ interaction. J Biol Chem 270: 7563-7567.
38. Mattson MP, Tomaselli KJ, Rydel RE (1993): Calcium-destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF. Brain Res 621:35-49.
39. McGeer PL, Akiyama H, Itagaki S, McGeer EG (1989): Immune system response in Alzheimer's disease. Can J Neurol Sci 16: 516-527.
40. Naiki H, Higuchi K, Hosokawa M, Takeda T (1989): Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavine T. Anal Biochem 177:244-249.
41. Naiki H, Higuchi K, Nakakuki K, Takeda T (1991): Kinetic analysis of amyloid fibril polymerization in vitro. Lab Invest 65:104-110.
42. Nakamura T, Shoji M, Harigaya T, Watanabe M, Hosoda K, Cheung TT, Shaffer LM, Golde TE, Younkin LH, Younkin SG, Hirai S (1994): Amyloid beta protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann Neurol 36: 903-911.
43. Oda T, Pasinetti GM, Osterburg HH, Anderson C, Johnson SA, Finch CE (1994): Purification and characterization of brain clusterin. Biochem Biophys Res Commun 204:1131-1136.
44. Pepys MB, Dyck RF, DeBeer FC, Skinner M, Cohen AS (1979): Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol 38:284-293.
45. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW (1991): In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563:311-314.
46. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW (1993): Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state. J Neurosci 13:1676-1687.
47. Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW (1995): Structure-activity analyses of β-amyloid peptides: Contributions of the β25-35 region to aggregation and neurotoxicity. J Neurochem 64:253-265.
48. Pirttila T, Mehta PD, Lehtimaki T, Kim KS, Sersen EA, Frey H, Nikkari T, Wisniewski HM (1995): Effect of apolipoprotein E4 allele on soluble β-amyloid protein concentrations in cerebrospinal fluid from patients with Alzheimer's disease and controls. In Iqbal K, Mortimer JA, Winblad B, Wisniewski HM (eds): "Research Advances in Alzheimer's Disease and Related Disorders." New York: John Wiley & Sons, pp 121-128.
49. Pitas RE, Boyles JK, Lee SH, Hui D, Weisgraber KH (1987): Lipoproteins and their receptors in the central nervous system. J Biol Chem 262:14352-14360.
50. Probst A, Brunnschweiler H, Lautenschlager C, Ulrich J (1987): A special type of senile plaque, possibly an initial stage. Acta Neuropathol 74:133-141.
51. 1-antichymotrypsin, in normal human cerebrospinal fluid. J Neurochem 58:88-94.
52. Rebeck GW, Reiter JS, Strickland DK, Hyman BT (1993): Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron 11:575-580.
53. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, Lieberburg I (1992): Complement activation by β-amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 89:10016-10020.
54. Roher A, Wolfe D, Palutke M, KuKuruga D (1986): Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein. Proc Natl Acad Sci USA 83: 2622-2666.
55. Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, Strittmatter WJ (1994): Apolipoprotein E associates with β amyloid peptide of Alzheimer's disease to form novel monofibrils. J Clin Invest 94:860-869.
56. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses D (1993): Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:9649-9653.
57. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, Zagorlki MG, Talafous J, Eisenberg M, Saunders AM, Roses AD, Goldgaber D (1994): Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA 91:8368-8372.
58. Seubert P, Vigo-Pelfry C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, McCormack R, Wolfert R, Selkoe D, Lieberburg I, Schenk D (1992): Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature 359:325-327.
59. Simmons LK, May PC, Tomaselli KJ, Rydel RE, Fuson KS, Brigham EF, Wright S, Lieberburg I, Becker GW, Brems DN, Li WY (1994): Secondary structure of amyloid β peptide correlates with neurotoxic activity in vitro. Mol Pharmacol 45:373-379.
60. Sipe JD (1992): Amyloidosis. Annu Rev Biochem 61:947-975.
61. Smyth MD, Cribbs DH, Tenner AJ, Schankle WR, Dick M, Kesslak JP, Cotman CW (1994): Decreased levels of C1q in cerebrospinal fluid of living Alzheimer patients correlate with disease state. Neurobiol Aging 15:609-614.
62. Snyder SW, Ladror US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA, Holzman TF (1994a): Amyloid-β aggregation: Selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys J 67: 1216-1228.
63. Snyder SW, Wang GT, Barrett L, Ladror US, Casuto D, Lee CM, Krafft GA, Holzman RB, Holzman TF (1994b): Complement C1q does not bind monomeric β-amyloid. Exp Neurol 128: 136-142.
64. Soto C, Castano EM, Prelli F, Kumar RA, Baumann M (1995): Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer's, Gelsolin and AA amyloids. FEBS Lett 371:110-114.
65. Strittmatter WJ, Weisgraber KH, Huang DY, Dong L-M, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD (1993): Binding of human apolipoprotein E to synthetic amyloid β peptide: Isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:8098-8102.
66. Swanson SJ, Christner RB, Mortensen RF (1992): Human serum amyloid P-component (SAP) selectively binds to immobilized or bound forms of C-reactive protein (CRP). Biochim Biophys Acta 1160:309-316.
67. Tagliavini F, Giaccone G, Frangione B, Bugiani O (1988): Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and non-demented individuals. Neurosci Lett 93:191-196.
68. Tan SY, Pepys MB (1994): Amyloidosis. Histopathology 25:403-414.
69. Ueda K, Fukui Y, Kageyama H (1994): Amyloid beta protein-induced neuronal cell death: Neurotoxic properties of aggregated amyloid beta protein. Brain Res 639:240-244.
70. Webster S, O'Barr S, Rogers J (1994): Enhanced aggregation and β structure of amyloid β peptide after co-incubation with C1q. J Neurosci Res 39:448-456.
71. Webster S, Glabe C, Rogers J (1995): Multivalent binding of complement protein C1q to the amyloid β-peptide promotes the nucleation phase of Aβ aggregation. Biochem Biophys Res Commun 217:869-875.
72. Weisgraber KH (1994): Apolipoprotein E: Structure-function relationships. Adv Prot Chem 45:249-301.
73. Wisniewski HM, Terry RD (1973): Reexamination of the pathogenesis of the senile plaques. Prog Neuropathol 11:1-26.
74. Wisniewski T, Castano E, Ghiso J, Frangione B (1993a): Cerebrospinal fluid inhibits Alzheimer β-amyloid fibril formation in vitro. Ann Neurol 34:631-633.
75. Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B (1993b): Apolipoprotein E: Binding to soluble Alzheimer beta-amyloid. Biochem Biophys Res Commun 192:359-365.
76. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B (1994): Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145:1030-1035.
77. Wood SJ, Maleeff B, Hart T, Wetzel R (1996): Physical, morphological and functional differences between pH 5.8 and 7.4 aggregates of the Alzheimer's amyloid peptide Aβ. J Mol Biol 256: 870-877.
78. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Harigaya Y (1988): Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol 77:113-119.
79. Zlokovic BV, Martel CL, Mackic JB, Matsubara E, Wisniewski T, McComb JG, Frangione B, Ghiso J (1994): Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid β. Biochem Biophys Res Commun 205:1431-1437.